Peter Nigrovic, MD, provides a practical guide to the diagnosis & treatment of macrophage activation syndrome (MAS) in children & adults.
An Approach to Physical Activity & Exercise in Axial Spondyloarthritis
‘Physical therapy is a mainstay of managing rheumatic diseases, but what’s the evidence, how do we monitor, and what types of therapy should we advocate?’ asks Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘Here, we provide some practical recommendations for the everyday rheumatologist.’ Physical activity, including occupational and recreational activities, is one of…
Rheumatic Manifestations of Diabetes (Mimics, Common Culprits & More)
Understanding the intersection of diabetes mellitus & rheumatic diseases, including lesser known rheumatic entities of diabetes, such as diabetic cheiroarthropathy, scleredema & diabetic myonecrosis, is crucial for accurate diagnosis.
A Practical Guide to Autoantibody Testing in Rheumatic Diseases
“ANA’s are some of most commonly ordered tests but what exactly are they and what do you do with a positive ANA? Check out the Editor’s Pick for October to learn more,” says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS.
B Cell-Depleting Therapy in SLE
“SLE has long been a disease with many clinical manifestations but few treatment options,” says Physician Editor Bharat Kumar, explaining why he thinks this article is a must-read. “That’s rapidly changing with advances in our knowledge of lupus, especially in the role of B-cells in triggering the onset and perpetuating disease activity of lupus.”
Palliative Care for Inclusion Body Myositis, a Case Report
“Our patients’ goals for their care aren’t always the same as ours. We’re typically focused on disease control, and they’re often focused on quality of life. Having ongoing discussions about care goals is the only way to know when it’s time to switch gears. Would you know when to refer your patients to palliative care?…
The ACR and CHEST Release 2 New ILD Guidelines
Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).